Publications and Presentations

Momentum 3 5-Year Outcomes

This study examines outcomes from the 5-year extended analysis of the MOMENTUM 3 trial, comparing HeartMate 3™ LVAD to HeartMate II™ LVAD

5-year Survival with LVAD Therapy in MOMENTUM 3

Mehra, MR. 5-Year Survival with LVAD Therapy in MOMENTUM 3. Presented at: European Society of Cardiology (ESC) Annual Meeting; August 28, 2022; Barcelona, Spain.

This extension of the MOMENTUM 3 study extended out 5 years and showed the superior treatment effect of the HeartMate 3 LVAD over HeartMate II LVAD on HRAEs, which was associated with improved survival at 5-years:

  • Improved survival was driven by a reduction in hemocompatibility-related deaths, e.g. thrombosis, stroke, and bleeding
  • This study demonstrates that median survival with the HM3 reliably exceeds 5 years, even in those patients with refractory heart failure who are ineligible for transplantation

MAT-2210315 v2.0